March 11, 2021

Q&A on vaccine manufacturing

The backdrop to successful COVID-19 vaccine development and roll out is the ability to manufacture vaccines quickly and at scale. This panel talked to the key steps involved in large scale vaccine manufacture, the different kinds of vaccines and what challenges they present in being able to scale-up and manufacture at pace, how we can adapt to make new generations of vaccines, and how these demands can be met both within the UK and globally.

Speakers included:

Dr Dave Tudor, Managing Director, Medicines Manufacturing Innovation Centre, Biologics & Quality

Steve Bagshaw, Non-Executive Director of the Centre for Process Innovation (CPI) and Non-Executive Chairman of Fujifilm Diosynth Biotechnologies

Dr Ian Muir, CEO of Porton Biopharma Ltd 

Prof Catherine Green, Head of the Nuffield Department of Medicine’s Clinical Biomanufacturing Facility (CBF) and Associate Professor at the Wellcome Centre for Human Genetics, University of Oxford